Molecular pathology of non-small cell carcinoma

被引:11
作者
Yatabe, Yasushi [1 ,2 ]
机构
[1] Natl Canc Ctr, Dept Diagnost Pathol, Tokyo, Japan
[2] Natl Canc Ctr, Dept Diagnost Pathol, 5-1-1 Tsukiji, Chuo Ku, Tokyo 1040045, Japan
基金
日本学术振兴会;
关键词
immune check-point inhibitors; lung cancer; molecular pathogenesis; oncogene addiction; two-compartment model; FACTOR-RECEPTOR GENE; IMMUNE CHECKPOINT INHIBITORS; TUMOR MUTATION BURDEN; LUNG-CANCER; EGFR MUTATIONS; TYROSINE KINASE; CLINICOPATHOLOGICAL FEATURES; RET REARRANGEMENTS; CLINICAL-FEATURES; PD-L1; EXPRESSION;
D O I
10.1111/his.15080
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Currently, lung cancer is treated by the highest number of therapeutic options and the benefits are based on multiple large-scale sequencing studies, translational research and new drug development, which has promoted our understanding of the molecular pathology of lung cancer. According to the driver alterations, different characteristics have been revealed, such as differences in ethnic prevalence, median age and alteration patterns. Consequently, beyond traditional chemoradiotherapy, molecular-targeted therapy and treatment with immune check-point inhibitors (ICI) also became available major therapeutic options. Interestingly, clinical results suggest that the recently established therapies target distinct lung cancer proportions, particularly between the EGFR/ALK and PD-1/PD-L1-positive subsets, e.g. the kinase inhibitors target driver mutation-positive tumours, whereas driver mutation-negative tumours respond to ICI treatment. These therapeutic efficacy-related differences might be explained by the molecular pathogenesis of lung cancer. Addictive driver mutations promote tumour formation with powerful transformation performance, resulting in a low tumour mutation burden, reduced immune surveillance, and subsequent poor response to ICIs. In contrast, regular tobacco smoke exposure repeatedly injures the proximal airway epithelium, leading to accumulated genetic alterations. In the latter pathway, overgrowth due to alteration and immunological exclusion against neoantigens is initially balanced. However, tumours could be generated from certain clones that outcompete immunological exclusion and outgrow the others. Consequently, this cancer type responds to immune check-point treatment. These pathogenic differences are explained well by the two-compartment model, focusing upon the anatomical and functional composition of distinct cellular components between the terminal respiratory unit and the air-conducting system. Two-compartment model in the putative molecular pathogenesis of lung cancer. The accumulation of genetic alterations with escaping immune surveillance is a key factor for tumours from the air-conducting system under the strong influence of tobacco smoke, whereas oncogene-addicted adenocarcinomas are driven by a single oncogenic mutation with powerful transformation activity.image
引用
收藏
页码:50 / 66
页数:17
相关论文
共 148 条
  • [1] Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
    Aggarwal, Rahul
    Huang, Jiaoti
    Alumkal, Joshi J.
    Zhang, Li
    Feng, Felix Y.
    Thomas, George V.
    Weinstein, Alana S.
    Friedl, Verena
    Zhang, Can
    Witte, Owen N.
    Lloyd, Paul
    Gleave, Martin
    Evans, Christopher P.
    Youngren, Jack
    Beer, Tomasz M.
    Rettig, Matthew
    Wong, Christopher K.
    True, Lawrence
    Foye, Adam
    Playdle, Denise
    Ryan, Charles J.
    Lara, Primo
    Chi, Kim N.
    Uzunangelov, Vlado
    Sokolov, Artem
    Newton, Yulia
    Beltran, Himisha
    Demichelis, Francesca
    Rubin, Mark A.
    Stuart, Joshua M.
    Small, Eric J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (24) : 2492 - +
  • [2] Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations
    Ahn, Myung-Ju
    Mendoza, Marvin Jonne L.
    Pavlakis, Nick
    Kato, Terufumi
    Soo, Ross A.
    Kim, Dong-Wan
    Liam, Chong Kin
    Hsia, Te-Chun
    Lee, Chee Khoon
    Reungwetwattana, Thanyanan
    Geater, Sarayut
    Chan, Oscar Siu Hong
    Prasongsook, Naiyarat
    Solomon, Benjamin J.
    Nguyen, Thi Thai Hoa
    Kozuki, Toshiyuki
    Yang, James Chih-Hsin
    Wu, Yi-Long
    Kam, Tony Shu
    Tan, Daniel Shao-Weng
    Yatabe, Yasushi
    [J]. CLINICAL LUNG CANCER, 2022, 23 (08) : 670 - 685
  • [3] Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis
    Alifu, Muyesar
    Tao, Min
    Chen, Xiao
    Chen, Jie
    Tang, Kejing
    Tang, Yubo
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [4] [Anonymous], 2016, Cancer Discov, V6, pOF7, DOI [10.1158/2159-8290.CD-NB2016-076, 10.1158/2159-8290.CD-NB2016-044]
  • [5] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Yokoi, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    de Castro Carpeno, J.
    Wadsworth, C.
    Melillo, G.
    Jiang, H.
    Huang, Y.
    Dennis, P. A.
    Ozguroglu, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) : 1919 - 1929
  • [6] RET receptor signaling: Dysfunction in thyroid cancer and Hirschsprung's disease
    Asai, N
    Jijiwa, M
    Enomoto, A
    Kawai, K
    Maeda, K
    Ichiahara, M
    Murakumo, Y
    Takahashi, M
    [J]. PATHOLOGY INTERNATIONAL, 2006, 56 (04) : 164 - 172
  • [7] Tracking Cancer Evolution through the Disease Course
    Bailey, Chris
    Black, James R. M.
    Reading, James L.
    Litchfield, Kevin
    Turajlic, Samra
    McGranahan, Nicholas
    Jamal-Hanjani, Mariam
    Swanton, Charles
    [J]. CANCER DISCOVERY, 2021, 11 (04) : 916 - 932
  • [8] Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma
    Barletta, Justine A.
    Perner, Sven
    Iafrate, A. John
    Yeap, Beow Y.
    Weir, Barbara A.
    Johnson, Laura A.
    Johnson, Bruce E.
    Meyerson, Matthew
    Rubin, Mark A.
    Travis, William D.
    Loda, Massimo
    Chirieac, Lucian R.
    [J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2009, 13 (8B) : 1977 - 1986
  • [9] Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
    Bell, DW
    Gore, I
    Okimoto, RA
    Godin-Heymann, N
    Sordella, R
    Mulloy, R
    Sharma, SV
    Brannigan, BW
    Mohapatra, G
    Settleman, J
    Haber, DA
    [J]. NATURE GENETICS, 2005, 37 (12) : 1315 - 1316
  • [10] ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
    Bergethon, Kristin
    Shaw, Alice T.
    Ou, Sai-Hong Ignatius
    Katayama, Ryohei
    Lovly, Christine M.
    McDonald, Nerina T.
    Massion, Pierre P.
    Siwak-Tapp, Christina
    Gonzalez, Adriana
    Fang, Rong
    Mark, Eugene J.
    Batten, Julie M.
    Chen, Haiquan
    Wilner, Keith D.
    Kwak, Eunice L.
    Clark, Jeffrey W.
    Carbone, David P.
    Ji, Hongbin
    Engelman, Jeffrey A.
    Mino-Kenudson, Mari
    Pao, William
    Iafrate, A. John
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) : 863 - 870